A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
← catalyst calendarNCT07215559 · readout ≤ 224 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
200estimated
Sites
42
Countries
Argentina, Australia, Puerto Rico +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-16 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
- Diabetes Mellitus, Type 2
Interventions
- Drug: Macupatide — also filed as LY3532226
- Drug: Eloralintide — also filed as LY3841136
- Drug: Macupatide Placebo
- Drug: Eloralintide Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change from Baseline in Body Weight
measured Baseline, Week 32
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed